Background: The chronic neuropathic form of Gaucher disease (GD3) is characterised by hepatosplenomegaly,
anaemia, thrombocytopenia, bone alterations and central neurological involvement. Enzyme replacement therapy
(ERT) has been demonstrated to be effective in non neuropathic Gaucher disease, but long term results in
patients with GD3 are still limited and contrasting. A possible role of genotype in determining the response to
ERT has been hypothesised